Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

What Was Tested

The trial (phase 3) is built around Semaglutide.

The goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (AIS).

It will also learn about the safety of semaglutide in AIS.

It had two arms (groups): semaglutide (experimental) and Standard medical management (placebo comparator).

Standard medical management. Participants will receive EVT, antiplatelet drugs, anticoagulation or combinations of these treatment modality according to national and institutional guidelines.

The registry classes the interventions as drug and other.

Who Took Part

Enrollment: 390 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: LVO stroke at terminal ICA, M1 or dominant M2 with an LKW-to-randomization ≤24 hours. Age ≥ 18 years old. National Institute of Health Stroke Scale ≥ 6 at the time of brain imaging. Acute LVO stroke due to thromboembolism or intracranial stenosis. Patients who received computer tomographic or magnetic resonance angiography.

The full record lists 8 inclusion and 14 exclusion criteria; among the exclusions: use of intravenous thrombolytic therapy (alteplase or tenecteplase); pre-stroke mrs \> 2 for patients \<80 years and \> 1 for patients ≥ 80 years old; intracranial hemorrhage or brain tumour on initial imaging (except small meningiomas).

How the Study Was Run

It was run as a randomized, parallel-group and single-blind study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Semaglutide group and the comparison group ran side by side rather than switching.

In this single-blind Semaglutide study one party knew the assignments and the other did not.

Those kept unaware of assignments: outcomes assessor.

It started in 2025-02 with completion listed for 2028-02.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: The ordinal shift of modified Rankin Scale (time frame: 90±14 days after procedure).

It also tracked 6 secondary outcomes, for example Proportion of patients with functional independence outcome (mRS 0-1) at day 90, Proportion of patients with functional independence outcome (mRS 0-2) at day 90, Proportion of patients with ambulatory and self-care capable outcome (mRS 0-3) at day 90, Neurological Function of Participants Assessed by National Institute of Health Stroke Scale, Health-related Quality of Life of Participants Assessed by EuroQol-5 Dimension-5 Level and Activities of Daily Living of Participants Assessed by Bathel Index.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide in 390 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.